Zura Bio Ltd. (94E)
XFRA 
Summary
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)
Zura Bio Limited (ZURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know
The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zura Bio Ltd. (94E) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zura Bio Ltd. ever had a stock split?
Zura Bio Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Kimberly Ann Davis CEO | XFRA Exchange | KYG9TY5A1016 ISIN |
| US Country | 30 Employees | - Last Dividend | - Last Split | 3 Sep 2021 IPO Date |
Overview
Zura Bio Limited is a forefront clinical-stage biotechnology firm with a dedicated focus on creating innovative treatments for immune and inflammatory diseases. Based in Henderson, Nevada, this dynamic company leverages cutting-edge science to address the unmet needs in immunology and inflammation. Zura Bio Limited's research and development efforts are concentrated on designing molecules that can modulate critical biological pathways involved in a wide range of immune-mediated disorders, highlighting its commitment to improving patient outcomes and advancing healthcare.
Products and Services
Zura Bio Limited's product pipeline showcases a robust focus on novel therapeutic candidates that promise to transform the treatment landscape of immune and inflammatory diseases:
- ZB-168: Anti IL7R a Inhibitor - This pioneering therapeutic candidate represents a significant breakthrough in the treatment of diseases driven by the IL7 and TSLP biological pathways. ZB-168's mechanism of action involves the inhibition of the IL-7 receptor alpha (IL7Rα), a crucial element in the pathophysiology of various immune-mediated diseases. By targeting this receptor, ZB-168 aims to modulate the immune system in a way that can lead to better disease control and improved quality of life for patients suffering from conditions influenced by IL7 and TSLP.
- Torudokimab: Monoclonal Antibody against IL33 - Currently in Phase 2 clinical trial, Torudokimab is a monoclonal antibody designed to neutralize interleukin 33 (IL-33). IL-33 is an important cytokine that plays a pivotal role in inflammation and autoimmunity. By neutralizing IL-33, Torudokimab has the potential to offer relief to patients with diseases where IL-33 is implicated in disease pathology. Its development underscores Zura Bio Limited’s effort to address critical gaps in available treatments for immune-related conditions.
Contact Information
